Intron A Related Clinical Trials
Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma [Recruiting]
A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma [Recruiting]
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600 AM2) [Recruiting]
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients [Recruiting]
Study Comparing Reduction and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1 [Recruiting]
Intron A for the Treatment of Hypertrophic Scar [Not yet recruiting]
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron [Terminated]
Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. [Active, not recruiting]
Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C [Completed]
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine [Recruiting]
5-Aza-2-Deoxycitidine With Pegylated Interferon-Alfa 2B: A Phase I Study With Molecular Correlates [Recruiting]
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML [Active, not recruiting]
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) [Active, not recruiting]
Study of PEG-Intron for Plexiform Neurofibromas [Recruiting]
Extended Treatment With PEG-Intron and Rebetol in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685AM3) [Active, not recruiting]
Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)(COMPLETED) [Completed]
Peg-Intron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (Study P04498) [Active, not recruiting]
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance [Recruiting]
PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy [Completed]
Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta [Recruiting]
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma [Active, not recruiting]
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With Chronic Hepatitis C [Active, not recruiting]
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma [Active, not recruiting]
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer [Recruiting]
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors [Completed]
Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer [Active, not recruiting]
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma [Active, not recruiting]
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon [Completed]
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma [Active, not recruiting]
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma [Active, not recruiting]
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma [Completed]
A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma [Completed]
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease [Completed]
Three Regimens of PEG-Intron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548AM2)(COMPLETED) [Completed]
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer [Active, not recruiting]
CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders) [Completed]
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer [Active, not recruiting]
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma [Not yet recruiting]
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy [Completed]
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia [Active, not recruiting]
Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma [Active, not recruiting]
Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer
Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy [Completed]
Interferon-Alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia [Active, not recruiting]
Interferon Alfa in Treating Children With HIV-Related Cancer [Active, not recruiting]
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors [Recruiting]
PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370AM2)(COMPLETED) [Completed]
Interferon Alfa-2b in Treating Patients Who Have Undergone Surgery for High-Risk or Metastatic Melanoma [Recruiting]
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders [Terminated]
Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients [Completed]
High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831AM1) [Active, not recruiting]
Sodium Stibogluconate and Interferon Alfa-2b Followed By Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Advanced Melanoma or Other Cancer [Not yet recruiting]
Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma [Active, not recruiting]
A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma [Completed]
Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144) [Active, not recruiting]
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3 [Completed]
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies [Recruiting]
Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B [Active, not recruiting]
Pegylated Interferon-Alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB [Active, not recruiting]
SCH 503034 Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659)(COMPLETED) [Completed]
Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4 [Completed]
PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer [Active, not recruiting]
Phase III PEG-Intron in HIV-Infected Patients (Study P00738)(COMPLETED) [Completed]
Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma [Recruiting]
IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma [Not yet recruiting]
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM1) [Recruiting]
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC [Recruiting]
Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin [Recruiting]
Interferon-Gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-Responders [Recruiting]
Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538AM1)(COMPLETED) [Completed]
Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders [Recruiting]
Gamma Interferon Therapy for Chronic Hepatitis C [Completed]
Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin [Active, not recruiting]
Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer [Active, not recruiting]
Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients [Recruiting]
Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C [No longer recruiting]
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer [Active, not recruiting]
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma [Recruiting]
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma [No longer recruiting]
A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood [Completed]
Sorafenib With or Without Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer [Recruiting]
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer [Active, not recruiting]
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma [Recruiting]
Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211) [Completed]
The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS [Completed]
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma [Completed]
Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin [Recruiting]
Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children [Active, not recruiting]
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer [Active, not recruiting]
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer [No longer recruiting]
Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma [No longer recruiting]
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors [Completed]
Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Active, not recruiting]
|
